☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
biogen
Biogen and Neomorph Collaborate to Discover and Develop Molecular Glue Degraders (MGD)
October 30, 2024
Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024
October 28, 2024
Biogen’s Felzartamab Gains the US FDA’s Breakthrough Therapy Designation to Treat AMR in Kidney Transplant Recipients
October 11, 2024
The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19
June 26, 2024
For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio
May 23, 2024
Biogen Receives EMA’s CHMP Positive Opinion for Tofidence (Biosimilar, Roactemra)
April 25, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.